Overview

A Phase II Study in Patients With Alopecia Areata

Status:
Completed

Trial end date:
2021-06-29

Target enrollment:

Participant gender:

Summary

This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.

Phase:

Phase 2

Details

Lead Sponsor:

Reistone Biopharma Company Limited